What is Kiora Pharma's earnings per share (EPS)?

Kiora Pharma (KPHMW) reported diluted earnings per share of -$2.64 for fiscal year 2025. This represents a -403.4% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Kiora Pharma (KPHMW) Financials

KPHMW

FY2025 annual

Revenue $0 -100.0% YoY

Net Income -$11K -401.4% YoY

EPS (Diluted) -$2.64 -403.4% YoY

Free Cash Flow -$10.1M -217.8% YoY

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 7, 2026 Currency USD FYE December

Newest figures come from the 10-K for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the KPHMW SEC filings page.

Kiora Pharma (KPHMW) reported $0 in revenue for fiscal year 2025, down 100.0% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI KPHMW FY2025 2026-08-30

The dominant mechanic is a sharp operating reversal: development spending drives cash needs while fixed-asset reinvestment remains minimal.

Operating cash flow moved from $8.6M in FY2024 to -$10.0M in FY2025 despite minimal capital expenditures, so the cash reversal reflects operating spending rather than heavier fixed-asset reinvestment. This makes cash conversion broadly consistent with the operating result, not a separate accounting-versus-cash divergence.

R&D intensity increased: spending rose 37.4% to $10.8M in FY2025. Operating income simultaneously reversed from $4.5M in FY2024 to -$12.8M, making the operating cost base the visible driver of the reversal.

FY2025 liabilities of $8.1M stood below $16.1M of equity, indicating an equity-heavy balance-sheet posture rather than dependence on debt. Despite that structure, FY2024 operating profit almost entirely disappeared before net income, showing that below-operating items or taxes materially shaped reported earnings.

Financial Health Signals

Financial health score not available

Kiora Pharma does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.

Piotroski F-Score Partial

1/7

Kiora Pharma passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). No profitability signals pass, 1 of 2 leverage/liquidity signals pass, neither operating efficiency signal passes.

Earnings Quality No Cash Backing

N/A

Kiora Pharma reported a net loss of $11K while operations used $10.0M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Kiora Pharma reported an operating loss of $12.8M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

EBITDA

-$2.2M

YoY+7.9%

QoQ+11.9%

Kiora Pharma's EBITDA was -$2.2M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 7.9% from the same quarter a year earlier. Against the prior quarter it is up 11.9%.

Net Income

-$2.1M

YoY+3.4%

QoQ+14.0%

Kiora Pharma reported -$2.1M in net income in Q2 2026. This represents an increase of 3.4% from the same quarter a year earlier. Against the prior quarter it is up 14.0%.

EPS (Diluted)

-$0.34

QoQ+41.4%

Kiora Pharma earned -$0.34 per diluted share (EPS) in Q2 2026. Against the prior quarter it is up 41.4%.

Revenue

Not reported for Q2 2026.

Cash & Balance Sheet

Free Cash Flow

-$1.9M

YoY+50.1%

QoQ+39.5%

Kiora Pharma recorded an outflow of $1.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 50.1% from the same quarter a year earlier. Against the prior quarter it is up 39.5%.

Cash & Debt

$7.1M

YoY+588.2%

QoQ-35.4%

5Y CAGR+14.1%

10Y CAGR-1.3%

Kiora Pharma held $7.1M in cash as of Q2 2026; long-term debt is not reported for that period.

Shares Outstanding

QoQ-0.2%

5Y CAGR-18.9%

10Y CAGR-6.8%

Kiora Pharma had 4M shares outstanding in Q2 2026. Against the prior quarter it is down 0.2%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Return on Equity

-12.3%

YoY-2.6pp

QoQ+5.0pp

Kiora Pharma's ROE was -12.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 2.6 percentage points from the same quarter a year earlier. Against the prior quarter it is up 5.0 percentage points.

Gross Margin

Not reported for Q2 2026.

Operating Margin

Not reported for Q2 2026.

Net Margin

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$2.1M

YoY-19.8%

QoQ-2.2%

Kiora Pharma invested $2.1M in research and development in Q2 2026. This represents a decrease of 19.8% from the same quarter a year earlier. Against the prior quarter it is down 2.2%.

Capital Expenditures

$23K

YoY-27.1%

QoQ+367.4%

Kiora Pharma invested $23K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 27.1% from the same quarter a year earlier. Against the prior quarter it is up 367.4%.

Share Buybacks

Not reported for Q2 2026.

KPHMW Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KPHMW quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	N/A	$0-100.0%	$16.0M	$0	N/A	$0-100.0%	$12K-99.6%	$2.7M+62.5%	$1.7M+305.5%	$408K-39.1%	$669K	$0	N/A
R&D Expenses	N/A	$10.8M+37.5%	$7.8M+94.7%	$4.0M+16.8%	$3.4M-35.5%	$5.4M+50.0%	$3.6M-33.8%	$5.4M-33.1%	$8.1M-22.0%	$10.3M+22.7%	$8.4M+210.0%	$2.7M+411.6%	$531K
SG&A Expenses	N/A	$5.7M+3.7%	$5.5M+18.9%	$4.7M-43.7%	$8.3M+55.5%	$5.3M+14.3%	$4.7M+5.7%	$4.4M-0.8%	$4.4M-4.2%	$4.6M-17.1%	$5.6M+41.2%	$4.0M+105.1%	$1.9M
Operating Income	N/A	-$12.8M-384.5%	$4.5M+135.8%	-$12.6M-2.3%	-$12.3M+13.5%	-$14.2M-107.3%	-$6.9M	N/A	-$10.8M	N/A	N/A	N/A	N/A
EBITDA	N/A	-$12.8M-382.7%	$4.5M+136.1%	-$12.5M-2.2%	-$12.3M+13.5%	-$14.2M-107.6%	-$6.8M	N/A	-$10.8M	N/A	N/A	N/A	N/A
Interest Expense	N/A	$20K-6.9%	$21K+92.7%	$11K+29.5%	$9K+25.5%	$7K+63.7%	$4K+1188.0%	$325-68.8%	$1K-14.4%	$1K+341.8%	$275-100.0%	$1.9M+337.9%	$442K
Income Tax	N/A	-$1.3M-162.1%	$2.1M+2186.3%	$90K+179.9%	-$113K+41.3%	-$193K-1697.7%	$12K-87.4%	$95K+10.9%	$86K+106.4%	-$1.3M	$0	N/A	N/A
Net Income	N/A	-$11K-401.4%	$4K+128.7%	-$13K+99.9%	-$13.6M+1.4%	-$13.8M-100.7%	-$6.9M+3.3%	-$7.1M+34.4%	-$10.8M+18.2%	-$13.2M+0.9%	-$13.3M-59.1%	-$8.4M-440.6%	-$1.6M
EPS (Basic)	N/A	-$2.60-379.6%	$0.93+3927.2%	-$0.02+99.9%	-$18.55+67.5%	-$57.12-3733.6%	-$1.49	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$2.51	-$2.64-403.4%	$0.87	-$0.02	-$18.55	-$57.12	-$1.49	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	4M-0.5%	4M	538,007	732,303	241,099	5M	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	N/A	N/A	N/A	$0	$0-100.0%	$0-100.0%	N/A	$0
R&D Expenses	$2.1M-19.8%	$2.1M-16.1%	N/A	$2.7M+24.9%	$2.6M+26.4%	$2.5M+50.3%	N/A	$2.2M+101.4%
SG&A Expenses	$1.4M+2.2%	$1.6M+8.2%	N/A	$1.4M+4.5%	$1.4M-12.0%	$1.5M+14.9%	N/A	$1.4M-2.5%
Operating Income	-$2.2M+7.6%	-$2.5M-7.7%	N/A	-$794K+77.9%	-$2.4M+5.8%	-$2.3M-117.6%	N/A	-$3.6M+39.1%
EBITDA	-$2.2M+7.9%	-$2.5M-7.3%	N/A	-$784K+78.2%	-$2.4M+5.7%	-$2.3M-117.6%	N/A	-$3.6M+39.1%
Income Tax	$0+100.0%	$0-100.0%	N/A	-$643K	-$112K	$123K	N/A	$0
Net Income	-$2.1M+3.4%	-$2.4M-10.3%	N/A	$27K+100.8%	-$2.2M+3.1%	-$2.2M-116.3%	N/A	-$3.4M+40.8%
EPS (Basic)	-$0.34+37.0%	-$0.58-11.5%	-$1.56-35.7%	$0.01+101.2%	-$0.54-1.9%	-$0.52-111.1%	-$1.15-2975.0%	-$0.81+88.9%
EPS (Diluted)	-$0.34	-$0.58-11.5%	-$1.60-53.8%	$0.01	-$0.54-1.9%	-$0.52	-$1.04	-$0.81
Diluted Shares (Avg)	6M	4M-1.0%	N/A	4M	4M-4.4%	4M	N/A	4M

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.

KPHMW Balance Sheet

KPHMW quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$24.3M-33.5%	$36.5M+166.1%	$13.7M-26.6%	$18.7M-7.2%	$20.1M+31.5%	$15.3M+51.3%	$10.1M-29.2%	$14.3M-0.2%	$14.3M+47.0%	$9.7M+2.3%	$9.5M+576.0%	$1.4M
Current Assets	$21.7M-26.8%	$29.7M+527.0%	$4.7M-38.3%	$7.7M-14.6%	$9.0M+420.8%	$1.7M-60.1%	$4.3M-49.0%	$8.5M+0.2%	$8.5M+103.6%	$4.2M-56.0%	$9.4M+4219.0%	$219K
Cash & Equivalents	$8.7M+129.3%	$3.8M+54.5%	$2.5M-58.8%	$6.0M-24.1%	$7.9M+562.5%	$1.2M-68.6%	$3.8M-52.8%	$8.0M+2.5%	$7.8M+114.7%	$3.6M-56.7%	$8.4M+4926.4%	$167K
Short-Term Investments	$8.4M-63.5%	$23.0M	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Accounts Receivable	$1.5M+153.3%	$601K	$0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Goodwill	N/A	N/A	N/A	$0	$0-100.0%	$3.6M+138.0%	$1.5M0.0%	$1.5M0.0%	$1.5M	N/A	N/A	N/A
Total Liabilities	$8.1M-24.2%	$10.7M+41.1%	$7.6M+4.6%	$7.3M+31.0%	$5.6M-0.4%	$5.6M+59.7%	$3.5M-34.7%	$5.3M-67.1%	$16.2M+61.4%	$10.1M+194.1%	$3.4M-92.9%	$48.2M
Current Liabilities	$3.6M-39.6%	$6.0M+267.7%	$1.6M-50.1%	$3.3M+103.3%	$1.6M-18.9%	$2.0M+40.3%	$1.4M-63.4%	$3.9M-73.9%	$14.8M+103.0%	$7.3M+113.6%	$3.4M-31.9%	$5.0M
Non-Current Liabilities	$4.5M-4.7%	$4.7M-21.0%	$6.0M+49.3%	$4.0M+1.4%	$3.9M+9.8%	$3.6M+73.0%	$2.1M+40.2%	$1.5M+5.8%	$1.4M-49.2%	$2.8M	$0-100.0%	$43.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	$278K	$0	N/A	N/A	N/A	N/A	N/A
Total Equity	$16.1M-37.4%	$25.8M+321.6%	$6.1M-46.4%	$11.4M-21.8%	$14.6M+49.8%	$9.7M+46.9%	$6.6M-25.9%	$8.9M+563.8%	-$1.9M-484.9%	-$329K-105.4%	$6.1M+113.0%	-$46.8M
Retained Earnings	-$154.2M-7.6%	-$143.4M+2.4%	-$147.0M-9.3%	-$134.5M-11.2%	-$120.9M-12.9%	-$107.1M-6.8%	-$100.2M-7.6%	-$93.2M-1.5%	-$91.8M-16.8%	-$78.6M-20.4%	-$65.3M-14.8%	-$56.9M

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$23.8M-25.6%	$21.2M-37.6%	$24.3M-33.5%	$29.9M-22.5%	$31.9M-21.7%	$34.0M-19.8%	$36.5M+166.1%	$38.5M+142.3%
Current Assets	$21.3M-14.0%	$18.7M-31.1%	$21.7M-26.8%	$22.7M-28.3%	$24.7M-22.3%	$27.1M-19.0%	$29.7M+527.0%	$31.7M+353.3%
Cash & Equivalents	$7.1M+588.2%	$11.0M+190.5%	$8.7M+129.3%	$5.5M-2.3%	$1.0M-84.4%	$3.8M-87.9%	$3.8M+54.5%	$5.6M+4.4%
Short-Term Investments	$9.8M-50.3%	$2.9M-85.7%	$8.4M-63.5%	$13.9M-40.7%	$19.6M-7.6%	$20.3M	$23.0M	$23.4M
Accounts Receivable	$1.1M-54.9%	$1.5M+15.4%	$1.5M+153.3%	$1.2M-32.0%	$2.4M+80.3%	$1.3M+604.4%	$601K	$1.8M
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$6.9M-29.5%	$7.3M-29.3%	$8.1M-24.2%	$7.5M-12.1%	$9.8M+27.3%	$10.3M+36.9%	$10.7M+41.1%	$8.5M+8.8%
Current Liabilities	$2.4M-25.6%	$2.8M-46.9%	$3.6M-39.6%	$2.6M-26.9%	$3.2M+92.4%	$5.3M+231.1%	$6.0M+267.7%	$3.5M+67.9%
Non-Current Liabilities	$4.5M-31.4%	$4.5M-10.9%	$4.5M-4.7%	$4.9M-1.6%	$6.6M+9.5%	$5.0M-15.1%	$4.7M-21.0%	$5.0M-13.0%
Total Equity	$16.9M-23.8%	$13.9M-41.2%	$16.1M-37.4%	$22.4M-25.4%	$22.1M-33.2%	$23.7M-32.1%	$25.8M+321.6%	$30.0M+270.6%
Retained Earnings	-$158.7M-7.4%	-$156.6M-7.6%	-$154.2M-7.6%	-$147.7M-6.1%	-$147.7M-8.8%	-$145.6M-9.0%	-$143.4M+2.4%	-$139.2M+3.8%

Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.

KPHMW Cash Flow Statement

KPHMW quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$8.5M	-$10.0M-216.4%	$8.6M+189.6%	-$9.6M+8.4%	-$10.4M+2.3%	-$10.7M-45.9%	-$7.3M+10.3%	-$8.2M+24.8%	-$10.8M-67.7%	-$6.5M+23.1%	-$8.4M-88.7%	-$4.5M-369.1%	-$951K
Depreciation & Amortization	N/A	$25K+29.1%	$19K-62.9%	$52K+24.5%	$42K-8.1%	$45K+35.6%	$33K-35.4%	$52K+34.3%	$38K+99.5%	$19K+272.0%	$5K+312.5%	$1K-27.1%	$2K
Stock-Based Compensation	N/A	$900K+37.1%	$657K-13.0%	$755K+63.2%	$462K-45.1%	$842K+16.4%	$724K-15.1%	$852K-2.6%	$875K+0.6%	$870K+70.3%	$511K-58.3%	$1.2M+4467.2%	$27K
Capital Expenditures	$107K	$111K+1670.9%	$6K	$0	$0-100.0%	$64K+218.1%	$20K	$0-100.0%	$20K-45.9%	$37K	$0	N/A	N/A
Free Cash Flow	-$8.6M	-$10.1M-217.8%	$8.6M+189.5%	-$9.6M+8.4%	-$10.4M+2.9%	-$10.7M-46.4%	-$7.3M+10.0%	-$8.2M+24.9%	-$10.9M-67.0%	-$6.5M+22.7%	-$8.4M	N/A	N/A
Investing Cash Flow	$9.6M	$14.4M+163.7%	-$22.7M	$0-100.0%	$6K+104.1%	-$157K+35.8%	-$244K	$0+100.0%	-$270K-629.7%	-$37K-121.2%	$175K	N/A	N/A
Financing Cash Flow	$4.9M	$266K-98.3%	$15.5M+159.8%	$6.0M-30.8%	$8.6M-51.0%	$17.6M+251.8%	$5.0M+27.5%	$3.9M-65.3%	$11.3M+5.9%	$10.7M+205.1%	$3.5M	N/A	N/A

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$1.9M+50.3%	-$3.2M-16.9%	-$2.2M+3.2%	-$1.3M-238.4%	-$3.8M-1.9%	-$2.7M-119.8%	-$2.3M+12.7%	$920K+136.5%
Depreciation & Amortization	$11K+213.8%	$11K+3221.7%	$11K+77.7%	$11K+403.7%	$3K-45.9%	$318-93.5%	$6K-25.5%	$2K-81.5%
Stock-Based Compensation	N/A	$210K+41.0%	N/A	N/A	N/A	$149K-15.3%	N/A	N/A
Capital Expenditures	$23K-27.1%	$5K	$78K+73.6%	$431	$32K	$0	-$45K	$0
Free Cash Flow	-$1.9M+50.1%	-$3.2M-17.1%	-$2.3M+1.7%	-$1.3M-238.4%	-$3.8M	-$2.7M	-$2.3M+11.0%	$920K+136.5%
Investing Cash Flow	-$6.9M-1137.3%	$5.4M+102.1%	$5.3M+1008.2%	$5.7M+398.9%	$664K+103.1%	$2.7M	$483K	-$1.9M
Financing Cash Flow	$4.9M+1753.7%	-$842	$296	$0	$265K+5.9%	$0-100.0%	$0+100.0%	$0

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

KPHMW Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

KPHMW quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Margin	N/A	28.1%	N/A	N/A	N/A	-56960.5%	N/A	-656.3%	N/A	N/A	N/A	N/A
Net Margin	N/A	0.0%	N/A	N/A	N/A	-56901.6%	-264.2%	-654.2%	-3243.5%	-1993.8%	N/A	N/A
Return on Equity	-0.1%-0.1pp	0.0%+0.2pp	-0.2%+118.9pp	-119.1%-24.6pp	-94.5%-23.9pp	-70.5%+36.6pp	-107.2%+13.8pp	-121.0%	N/A	N/A	-137.8%	N/A
Return on Assets	0.0%-0.1pp	0.0%+0.1pp	-0.1%+72.6pp	-72.7%-4.3pp	-68.4%-23.6pp	-44.8%+25.3pp	-70.2%+5.5pp	-75.7%+16.7pp	-92.4%+44.7pp	-137.1%-48.9pp	-88.2%+22.1pp	-110.3%
Current Ratio	5.99+1.0x	4.94+2.0x	2.90+0.6x	2.35-3.2x	5.59+4.7x	0.87-2.2x	3.06+0.9x	2.19+1.6x	0.570.0x	0.57-2.2x	2.76+2.7x	0.04
Debt-to-Equity	0.50+0.1x	0.42-0.8x	1.24+0.6x	0.64+0.3x	0.38+0.4x	0.030.0x	0.00-0.6x	0.60	N/A	N/A	0.56	N/A
Asset Turnover	0.00-0.4x	0.44+0.4x	0.00	N/A	0.000.0x	0.00-0.3x	0.27+0.1x	0.12+0.1x	0.030.0x	0.07+0.1x	0.00	N/A
FCF Margin	N/A	53.4%	N/A	N/A	N/A	-60844.6%	-303.6%	-657.4%	-1596.4%	-1257.1%	N/A	N/A

Metric	Q2'2610-K	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Return on Equity	-12.3%-2.6pp	-17.3%-8.1pp	N/A	0.1%+11.5pp	-9.7%-3.0pp	-9.3%-47.8pp	N/A	-11.4%+59.7pp
Return on Assets	-8.7%-2.0pp	-11.4%-4.9pp	N/A	0.1%+8.9pp	-6.7%-1.3pp	-6.5%-38.1pp	N/A	-8.9%+27.4pp
Current Ratio	8.97+1.2x	6.68+1.5x	5.99+1.0x	8.79-0.2x	7.76-11.5x	5.14-15.9x	4.94+2.0x	8.97+5.6x
Debt-to-Equity	0.410.0x	0.52+0.1x	0.50+0.1x	0.33+0.1x	0.44+0.2x	0.44+0.2x	0.42-0.8x	0.28-0.7x
Asset Turnover	N/A	N/A	N/A	0.000.0x	0.000.0x	0.00-0.4x	N/A	0.000.0x

Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, FCF Margin.

Where Kiora Pharma Ranks

Frequently Asked Questions

What is Kiora Pharma's annual revenue?

Kiora Pharma (KPHMW) reported $0 in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Kiora Pharma's revenue growing?

Kiora Pharma (KPHMW) revenue declined by 100.0% year-over-year, from $16.0M to $0 in fiscal year 2025.

Is Kiora Pharma profitable?

No, Kiora Pharma (KPHMW) reported a net income of -$11K in fiscal year 2025.

What is Kiora Pharma's EBITDA?

Kiora Pharma (KPHMW) had EBITDA of -$12.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Kiora Pharma's return on equity (ROE)?

Kiora Pharma (KPHMW) has a return on equity of -0.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Kiora Pharma's free cash flow?

Kiora Pharma (KPHMW) recorded an outflow of $10.1M in free cash flow during fiscal year 2025. This represents a -217.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Kiora Pharma's operating cash flow?

Kiora Pharma (KPHMW) recorded an outflow of $10.0M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Kiora Pharma's total assets?

Kiora Pharma (KPHMW) had $24.3M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Kiora Pharma's capital expenditures?

Kiora Pharma (KPHMW) invested $111K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Kiora Pharma spend on research and development?

Kiora Pharma (KPHMW) invested $10.8M in research and development during fiscal year 2025.

How many shares does Kiora Pharma have outstanding?

Kiora Pharma (KPHMW) had 4M shares outstanding as of fiscal year 2025.

What is Kiora Pharma's current ratio?

Kiora Pharma (KPHMW) had a current ratio of 5.99 as of fiscal year 2025, which is generally considered healthy.

What is Kiora Pharma's debt-to-equity ratio?

Kiora Pharma (KPHMW) had a debt-to-equity ratio of 0.50 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Kiora Pharma's return on assets (ROA)?

Kiora Pharma (KPHMW) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Kiora Pharma's Piotroski F-Score?

Kiora Pharma (KPHMW) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Kiora Pharma's earnings high quality?

Kiora Pharma (KPHMW) reported a net loss of $11K while operations used $10.0M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Kiora Pharma cover its interest payments?

Kiora Pharma (KPHMW) reported an operating loss of $12.8M against $20K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.